Navigation Links
Anthera Updates Phase 3 Plans Following Results from the Phase 2b PEARL-SC Dose Ranging Study of Blisibimod
Date:6/27/2012

eceived written Scientific Advice from the European Medicines Agency (EMA) confirming the acceptability of the Company's proposed Phase 3 design for the treatment of severe systemic lupus erythematosus patients as a basis for a marketing authorization application (MAA).  The EMA feedback confirms that our development program, including the heightened SRI-5 endpoint, is acceptable and that positive results from Phase 3 clinical studies in a severe lupus population would support approval of the product. The EMA has endorsed the Company's proposed Phase 3 manufacturing plan, which includes utilization of the recently manufactured drug substance and the use of a pre-filled syringe.

"The 200mg weekly dose was clearly the most clinically effective blisibimod dose.  In the severe lupus patients the treatment effect is evident after 12 weeks with a numerically greater number of responders at all subsequent time points despite early withdrawal of background therapy.  This is particularly evident among the most severely ill patients who require aggressive corticosteroid therapy," said Colin Hislop, M.D., Chief Medical Officer and Senior Vice President. "The PEARL-SC results demonstrate an ability to clinically differentiate blisibimod from currently available lupus therapies."

In conjunction with this press release Anthera will host a conference call at 8:30 a.m. Eastern Time tomorrow, June 28, 2012.  U.S. and Canadian participants may dial (877) 312-8807; international participants may dial (253) 237-1190.  The Conference ID is 95674621. To access the 24-hour audio replay, U.S. and Canadian participants may dial (855) 859-2056; international participants may dial (404) 537-3406.  The conference ID for the replay is 95674621.  The audio replay will be available until July 5, 2012.

*SLE responder index - 5 (SRI-5) is a composite responder index evaluating various patient and physician reported clinical disease activity i
'/>"/>

SOURCE Anthera Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
2. Anthera Announces First Quarter 2012 Financial Report and Conference Call
3. Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
4. Neuralstem Updates ALS Stem Cell Trial Progress
5. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
6. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
7. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
8. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
9. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
10. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
11. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014  Cepheid (Nasdaq: ... group purchasing contract with Premier will end on ... Premier GPO will be able to continue their ... Baycare, HPA, MedAssets, Novation, and ROi, in addition ... directly with Cepheid. "Cepheid has always ...
(Date:7/30/2014)... , July 30, 2014  Unilife Corporation ("Unilife" ... a developer and supplier of injectable drug delivery ... manufacturing capacity, R&D, and facilities in response to ... its products and services. During the fourth quarter ... $16 million in capital expenditures and R&D above ...
(Date:7/30/2014)... Research and Markets has announced the addition of the ... report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... lower CAGR in developed countries; however, it is expected to witness ... , India , and Brazil ... the hematology analyzers and reagents market is driven by factors such ...
Breaking Medicine Technology:Cepheid Updates Status Of Premier Group Purchasing Organization (GPO) Agreement 2Cepheid Updates Status Of Premier Group Purchasing Organization (GPO) Agreement 3Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 2Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 3Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 4Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 5Hematology Analyzers & Reagents Market - Forecasts to 2019 2
(Date:7/30/2014)... Andover, NJ (PRWEB) July 30, 2014 Within weeks ... with excitement and promise. Each hopes this will be a time ... is reason for each to pause; it may not be as ... as 80% of students will switch their major at least once ... cost time and energy and the costs are exacerbated when switching ...
(Date:7/30/2014)... 30, 2014 Conducting Advanced Root ... Thinking Skills and Innovative Techniques to Improve the ... and FDAnews**, Sept. 17-18, 2014 – Raleigh, NC, ... #1 reason for 483 observations since 1997. , ... a successful CAPA program has never been more ...
(Date:7/30/2014)... Good Neighbor Community Services announced ... episode of Innovations with Ed Begley Jr, airing ... show times TBA. , In this segment, viewers ... vision to redefine the traditional approach to serving ... Through passion, innovation, determination, excellence, and collaboration, Good ...
(Date:7/30/2014)... 30, 2014 SF Cable, distributor of ... lowest prices on the internet with guaranteed customer satisfaction ... lengths and two colors. These lightning cords are MFI ... The high quality SF Cable Lightning to USB ... signal delivering faster charging and syncing. Compatible with the ...
(Date:7/30/2014)... Hamilton Facial Plastic Surgery is ... office on July 30th. After months of planning, Dr. ... the state-of-the-art suite, located only steps away from the ... for one-on-one patient comfort, shorter wait times, and generally ... Hamilton’s new office-suite will continue to provide the same ...
Breaking Medicine News(10 mins):Health News:Advice to College Freshman from Author Garrett Miller 2Health News:Advice to College Freshman from Author Garrett Miller 3Health News:FDAnews Workshop: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 17-18, 2014, Raleigh, NC 2Health News:FDAnews Workshop: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 17-18, 2014, Raleigh, NC 3Health News:FDAnews Workshop: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 17-18, 2014, Raleigh, NC 4Health News:Good Neighbor Community Services to be Featured in an Upcoming Episode of Innovations With Ed Begley, Jr. 2Health News:SF Cable Delivers Certified Lightning Cable in Multiple Sizes and Colors 2Health News:Hamilton Facial Plastic Surgery Opens New Carmel Office 2
... As injectable fillers,become mainstream it is no surprise ... alternatives to prevent facial wrinkles. Dr. Arnold,Klein, world-renowned ... says, "Fillers such as Artefill, Radiesse and Sculptra,contain ... into,human tissue, all of these products can cause ...
... ARLINGTON, Va., May 8 Who says the best,times ... The HealthCentral Network, Inc. (http://www.HealthCentral.com ) has recently,brought ... prove that along,with wrinkles and the responsibility of caring ... bring a smile to the face of others., ...
... An international,organization dedicated to furthering the advancement ... (GSK) Consumer Healthcare executive today,during an awards ... Ernestine Harris,GSK Consumer Healthcare,s U.S. director of ... Star" by the Healthcare Businesswomen,s Association,(HBA). The ...
... with human immunodeficiency virus (HIV), which leads to acquired ... According to the most recent estimates, released in ... HIV/AIDS (UNAIDS) and the World Health Organization (WHO), an ... currently. Although the rates of infection appear to ...
... Hill-Rom Holdings,Inc., (NYSE: HRC ) invites ... H.,Soderberg, president and chief executive officer, Hill-Rom. He ... New York on Wednesday, May 21,at 8:30 a.m. ... the live presentation via the internet,link at ...
... ("MDAC") is proud to announce that it has retained ... build a significant enterprise in one or,more select medical ... MDAC team combines a strong set of capabilities and ... excited to be working,with them in identifying and executing ...
Cached Medicine News:Health News:Dr. Arnold Klein Warns of Dangers With Permanent and Longer Lasting Injectable Fillers 2Health News:The HealthCentral Network Signs Spunky 'Midlife Gals' for Comedic Relief on Alzheimer's, Skin Care Sites 2Health News:GSK's Ernestine Harris Honored as Industry 'Rising Star' by Healthcare Businesswomen's Association 2Health News:GSK's Ernestine Harris Honored as Industry 'Rising Star' by Healthcare Businesswomen's Association 3Health News:Do antidepressants enhance immune function? 2
... flow while minimizing the pain ... the safety-engineered BD Microtainer Genie ... Lancet offers a full range ... capillary blood collection and protects ...
... Maximize blood flow and minimize pain ... the safety-engineered BD Microtainer Quikheel Lancet. ... surgical blade providing a precise and ... retracts into its casing, helping to ...
DAVINCI® performs all required steps primary tube sampling, reagent dispensing, microplate incubation, washing and optical reading....
The Minilyser offers a combination of three well proven instruments for fully automated processing of microplates. The Minilyser is the optimal fully automated ELISA and EIA equipment for laboratorie...
Medicine Products: